Cardiome Pharma (CRME) Reports a Q1 Loss
More News related to CRME
- Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans
- Cardiome Pharma (CRME) Announces Vernakalant Met Phase 3 Primary Endpoint European Comparator Study
- Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
- Cardiome Pharma (CRME) Reports a Q1 Loss
- Cardiome Pharma (CRME) Extends "Dutch Auction" Tender Offer
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Cardiome Pharma Corp. (NASDAQ: CRME) reports a Q1 loss of $0.01 vs. consensus of $0.17 profit. Revenues were $21.1 million vs. $26.78 million consensus.
Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
[SM]
Related Categories
EarningsStocks Mentioned
+0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
